Navigation Links
ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Date:4/8/2008

LEUVEN, Belgium, April 9 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, eye diseases and cancer, announces today that it has completed patient enrolment for its Phase II MITI IV study. The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients between four and twelve hours after the onset of the stroke.

MITI IV (Microplasmin in Treatment of Ischemic stroke - IntraVenous) is a Phase II, multicentre, double-blinded, placebo-controlled, ascending-dose clinical trial evaluating the safety of the intravenous administration of microplasmin in 40 patients with acute ischemic stroke. The trial is investigating three dose regimens of microplasmin (2, 3, and 4 mg/kg total dose) and placebo. The trial is also designed to provide preliminary efficacy data using radiographic assessments and plasma surrogate biomarkers. Clinical outcomes are assessed at seven days and 30 days post-treatment, and at each of these visits neurological assessments are performed.

Microplasmin is a truncated form of the natural human protein plasmin, which plays a key role in dissolving blood clots such as those that cause acute stroke. It is a direct-acting thrombolytic agent that has the potential to restore blood flow efficiently within an extended period after a stroke event and has potentially fewer side-effects than other thrombolytic agents. Currently the only approved pharmacologic treatment of acute ischemic stroke is tPA, an indirect-acting thrombolytic. However tPA must be administered within three hours after the stroke has occurred and has the risk of causing unwanted bleeding events.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commenting on today's announcement said: "I am very pleased that we have completed enrolment in this study. We look forward to the results, which shoul
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics Announces 2007 Full Year Results
2. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
3. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
4. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
5. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
6. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
7. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
8. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
9. Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers
10. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
11. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calabasas, CA (PRWEB) July 24, 2014 ... advancing the Global Supply Chain of the biotech ... annual SCM Innovation Awards, brought to you by ... premiere global organization of supply chain management professionals ... be given to stakeholders of the Biotech industry ...
(Date:7/24/2014)... BURLINGAME, Calif. , July 24, 2014  ECC ... Denver, Colorado with University College Hospital ... of a development project to finance, design, construct, and ... Ibadan, Nigeria . Under the first ... and prepare scoping documents and funding applications. UCH Ibadan ...
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Cell Culture Market 2014-2018" report to their ... Cell culture is the in vitro growth of ... research, cell studies, and biopharmaceutical production. Cell culture is ... Cell culture instruments and cell culture consumables are necessary ...
Breaking Biology Technology:Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2
... Inc. (Nasdaq: MITI ), a biopharmaceutical company ... inflammation and autoimmune diseases, today announced that its President ... Future Leaders in the Biotech Industry conference at the ... City on Thursday, April 2, 2009. A simultaneous ...
... Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) announced ... its exclusive financial advisor to assist in the evaluation ... potential sale of the Company or its major assets."We ... efficiently determining if there is a transaction more beneficial ...
... company focused on the discovery and development of ... of microbial,resistance, announces today the appointment of Dr. ... Novexel,s SAB is chaired by Dr.,David Shlaes who ... is currently,Adjunct Professor at the Department of Biology ...
Cached Biology Technology:Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009 2Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009 3Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company 2Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush 2Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush 3
(Date:7/25/2014)... Terra satellite show the different areas that have been affected ... The burn scars show up as reddish-brown splotches of color ... the remote parts of Eastern Russia in the Sakha Republic. ... instrument, it is still possible to see the smoke rising ... below show the devastating number of fires that have plagued ...
(Date:7/25/2014)... autism and disrupted brain development is an essential ... is largely unknown. However, thanks to funding from ... Washington University (GW) researcher Anthony-Samuel LaMantia, Ph.D. may ... answers to these key questions in the field ... pharmacology and physiology at the GW School of ...
(Date:7/25/2014)... Nearly 600 scientists from 25 countries and ... Meeting organized by the Genetics Society of America ... in Seattle. The conference will feature close to ... results on topics including gene expression and regulation, ... technologies, evolution, aging, and a variety of diseases. ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2
... Alex Pyron,s expertise is in family trees. Who is related ... they are now. But not for humans: reptiles. In ... the island led him to confirm the identity of 60 ... an author on snakes and expert on amphibians and reptiles, ...
... foodborne bacteria Listeria monocytogenes sickens about 2,500 ... worldwide, killing about 25-30% of those infected. Listeriosis is ... , and current methods for detecting the bacteria are ... developing an inexpensive biosensor to detect the pathogen in ...
... laser laboratory operational later this year, he will use ... bonds like a stringed musical instrument. Tokmakoff, the ... at the University of Chicago in January to tackle ... vibrational spectroscopy methods that he has developed. "He ...
Cached Biology News:Sri Lankan snake study reveals new species, rich biodiversity in island country 2Low-cost nano-biosensor to detect foodborne pathogen that causes listeriosis 2Low-cost nano-biosensor to detect foodborne pathogen that causes listeriosis 3Watery research theme to flow through new Tokmakoff lab 2Watery research theme to flow through new Tokmakoff lab 3
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Biology Products: